Biosearch Technologies said this week that it has signed a broad licensing and manufacturing agreement with Korea's Seegene covering fluorophore, quencher dye, and oligonucleotide technology.
Under the agreement, Novato, Calif.-based Biosearch has licensed to Seegene patents covering Biosearch's CAL Fluor and Quasar fluorophores and BHQ dark quencher dye.
In addition, Biosearch will manufacture research- and in vitro diagnostic-grade oligonucleotides for Seegene, the companies said.
Financial terms of the agreement were not disclosed.
Seegene, based in Seoul and with a subsidiary in Rockville, Md., will incorporate the fluorophores and oligonucleotides into its Magicplex and Anyplex molecular diagnostic systems, which use dual priming oligonucleotide technology and real amplicon detection, or READ, PCR.
Seegene currently sells several tests in Europe and Asia, but has not yet received approval to market any of its tests in the US. The company markets tests for seasonal influenza A subtype H1, H3, and 2009 novel H1N1 in Europe and Asia; and has been granted a Medical Device License in Canada for its Diarrhea-V ACE Detection test for multiple diarrhea-causing viral agents.
The company also recently launched MagicPlex Sepsis, a multi-pathogen screening test designed to identify more than 90 top sepsis-causing pathogens simultaneously; and the Anyplex MDR-TB test for simultaneously detecting tuberculosis and genetic mutations for multi-drug-resistant TB.